Rosalinda Madonna
Overview
Explore the profile of Rosalinda Madonna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
188
Citations
3116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davidson S, Andreadou I, Antoniades C, Bartunek J, Basso C, Brundel B, et al.
Cardiovasc Res
. 2025 Mar;
PMID: 40084813
Animal models offer invaluable insights into disease mechanisms but cannot entirely mimic the variability and heterogeneity of human populations, nor the increasing prevalence of multi-morbidity. Consequently, employing human samples-such as...
2.
Madonna R, Ghelardoni S
Eur J Clin Invest
. 2025 Jan;
e14386.
PMID: 39825683
Sotatercept binds free activins by mimicking the extracellular domain of the activin receptor type IIA (ACTRIIA). Additional ligands are BMP/TGF-beta, GDF8, GDF11 and BMP10. The binding with activins leads to...
3.
Mattioli A, Coppi F, Severino P, Penna C, Pagliaro P, Dei Cas A, et al.
Nutrients
. 2025 Jan;
17(1.
PMID: 39796548
Vitamin D is increasingly recognized for its role in cardiovascular health beyond its well-established effects on bone metabolism. This review synthesizes findings from observational studies, interventional trials, and meta-analyses to...
4.
Casto E, Celi A, Madonna R, De Caterina R, Di Cianni F, Talarico R, et al.
RMD Open
. 2025 Jan;
10(4.
PMID: 39794272
No abstract available.
5.
Madonna R, Biondi F
Vascul Pharmacol
. 2024 Nov;
157():107442.
PMID: 39571875
Sotatercept (brand name WINREVAIR, developed by Merck) is an activin receptor type IIA-Fc (ActRIIA-Fc), working by sequestering free activins. Sotatercept restores the balance between the activin proliferative pathway and the...
6.
Madonna R, Biondi F
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518603
Sotatercept acts as a type IIA-Fc activin receptor, thereby scavenging free activin from its physiological membrane receptor. Through this type of action, sotaterpect leads to a rebalancing of the proliferation...
7.
Biondi F, Alberti M, Montemaggi E, DAlleva A, Madonna R
Thromb Haemost
. 2024 Sep;
PMID: 39299271
Three mutually exclusive entities can underlie a postpulmonary embolism syndrome (PPES): not obstructed postpulmonary embolism syndrome (post-PE dyspnea), chronic thromboembolic pulmonary disease (CTEPD), and chronic thromboembolic pulmonary hypertension (CTEPH). Cardiorespiratory...
8.
Mattii L, Moscato S, Ippolito C, Polizzi E, Novo G, Zucchi R, et al.
Biomed Pharmacother
. 2024 Aug;
178:117278.
PMID: 39116784
Background: Empagliflozin (EMPA), a selective sodium-glucose cotransporter type 2 (SGLT2) inhibitor, has been shown to reduce major adverse cardiovascular events in patients with heart failure of different etiologies, although the...
9.
Madonna R, Biondi F, Ghelardoni S, DAlleva A, Quarta S, Massaro M
Eur J Intern Med
. 2024 Aug;
129:1-15.
PMID: 39095300
Pulmonary hypertension associated to left heart disease (PH-LHD) refers to a clinical and haemodynamic condition of pulmonary hypertension associated with a heterogeneous group of diseases affecting any of the compartments...
10.
Empagliflozin restores autophagy and attenuates ponatinib-induced cardiomyocyte senescence and death
Biondi F, Ghelardoni S, Moscato S, Mattii L, Barachini S, Novo G, et al.
Vascul Pharmacol
. 2024 Jul;
155:107300.
PMID: 38985602
No abstract available.